北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial
作者: Sima, L.1; Fang, W. X.2; Wu, X. M.3,4; Li, F.5
关键词: oxycodone ; pain ; paracetamol
刊名: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
发表日期: 2012-02-01
DOI: 10.1111/j.1365-2710.2010.01239.x
卷: 37, 期:1, 页:27-31
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: CONTROLLED-RELEASE OXYCODONE ; NONSTEROIDAL ANTIINFLAMMATORY DRUGS ; NEUROPATHIC PAIN ; ACETAMINOPHEN ; MANAGEMENT
英文摘要:

What is known and Objective: Bone-cancer pain is a common and refractory cancer pain. Opioids, on their own, do not control this type of pain well enough, and co-analgesics are necessary.

Methods: Patients with bone metastasis-related pain at Numeric Rating Scale 4 were enrolled to this randomized placebo-controlled trial. They had also received morphine or transdermal fentanyl patches for at least 1 week. During the 3-day efficacy phase, patients received placebo or 1-3 tablets of oxycodone/paracetamol (5/325 mg), four times daily for 3 days. All patients kept a daily pain diary. The primary endpoint was the Pain Intensity Difference (PID). Secondary endpoints were cases of breakthrough pain and rescue morphine consumption. Additional analyses included the Short Form-6 Dimensions (SF-6D) quality-of-life scale and a general impression (GI) of patient satisfaction with treatment at the end of the phase.

Results and Discussion: Of the 246 patients in the intent-to-treat set, 89.4% completed the 3-day efficacy phase. PIDs were 0.9 and 0.3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0.001), and 1.5 and 0.3 respectively on day 3 (P < 0.001). Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0.001). The SF-6D score decreased to 21.2 +/- 2.5 in the oxycodone/paracetamol group at the end of the phase (P = 0.001). In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.

What is new and Conclusion: Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.

语种: 英语
WOS记录号: WOS:000299549500005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/57058
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.China Japan Friendship Hosp, Natl Pain Management & Res Ctr, Beijing 100029, Peoples R China
2.Peking Univ, Dept Anesthesia, Hosp 1, Beijing 100871, Peoples R China
3.Chinese Acad Med Sci, Dept Polyclin, Canc Inst & Hosp, Beijing 100730, Peoples R China
4.Peking Union Med Coll, Beijing 100021, Peoples R China
5.Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China

Recommended Citation:
Sima, L.,Fang, W. X.,Wu, X. M.,et al. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS,2012,37(1):27-31.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sima, L.]'s Articles
[Fang, W. X.]'s Articles
[Wu, X. M.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sima, L.]‘s Articles
[Fang, W. X.]‘s Articles
[Wu, X. M.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace